27754198|t|JS ISH-ECCR-3 A NOVEL ALGORITHM FOR THE CASE DETECTION OF THE MOST COMMON FORM OF ENDOCRINE HYPERTENSION
27754198|a|Primary aldosteronism (PA) involves more than 11% of patients referred to specialized hypertension centers and, therefore, is much more common than commonly held. Moreover, it causes a damage to the heart, blood vessels and kidneys, which translates into a high rate of cardiovascular events, in excess to the degree of blood pressure raise. Along with the notion that a timely diagnosis entails a fundamental step for the choice of an appropriate therapy, which can correct the arterial hypertension and the hypokalemia, this justifies efforts to search for PA in the majority of the patients with hypertension. Unfortunately, because of the lack of the classical signs, as spontaneous or drug-induced hypokalemia and related symptoms, PA deceives diagnosis in the majority of the cases .The identification of a curable form of primary aldosteronism can be beneficial particularly in some subgroups of patients, namely those with drug - resistant hypertension, who are at high risk of primary aldosteronism. An aggressive diagnostic approach is necessary in these patients, who can benefit most from an accurate diagnosis. Knowledge of the sodium intake and drug effects on the aldosterone-renin ratio is a key element for the diagnosis in these challenging cases .With the latest work-up endorsed by the Endocrine Society Guidelines and supported by the results of the AQUARR Study, the diagnostic algorithm for PA can be substantially simplified. This means skipping the so-called confirmatory tests in most cases and thus rendering the screening of PA feasible and affordable. Hence, most centers can nowadays exploit use of a cost - effective strategy to screen for patients with primary aldosteronism. At variance, the identification of primary aldosteronism subtypes, which involves adrenal vein sampling (AVS), should only be undertaken at tertiary referral centers that have experience in performing and interpreting this minimally invasive test .Overall, long-term cure biochemical cure can be consistently achieved when adrenalectomy is based on AVS - based identification of lateralized aldosterone excess. Moreover, long-term cure of hypertension, defined as no need for antihypertensive drug treatment, can be achieved in about 45% of the cases, with an additional 40% showing a marked improvement in blood pressure control. Lack of blood pressure normalization can be explained by misdiagnosis and/or concomitant essential hypertension.
27754198	0	13	JS ISH-ECCR-3	T170	C0679508
27754198	16	21	NOVEL	T080	C0205314
27754198	22	31	ALGORITHM	T170	C0002045
27754198	40	44	CASE	T169	C0868928
27754198	45	54	DETECTION	T061	C1511790
27754198	67	73	COMMON	T081	C0205214
27754198	74	78	FORM	T169	C1522492
27754198	82	104	ENDOCRINE HYPERTENSION	T047	C0264641
27754198	105	126	Primary aldosteronism	T047	C1384514
27754198	128	130	PA	T047	C1384514
27754198	158	166	patients	T101	C0030705
27754198	179	190	specialized	T077	C1704211
27754198	191	203	hypertension	T047	C0020538
27754198	204	211	centers	T073,T093	C0475309
27754198	241	247	common	T081	C0205214
27754198	281	287	causes	T169	C0015127
27754198	290	296	damage	T169	C1883709
27754198	304	309	heart	T023	C0018787
27754198	311	324	blood vessels	T023	C0005847
27754198	329	336	kidneys	T023	C0022646
27754198	362	371	high rate	T080	C0205082
27754198	375	396	cardiovascular events	T033	C1320716
27754198	401	407	excess	T080	C1979886
27754198	415	421	degree	T080	C0441889
27754198	425	445	blood pressure raise	T033	C0497247
27754198	476	482	timely	T080	C3827828
27754198	483	492	diagnosis	T060	C0430022
27754198	493	500	entails	T080	C0027552
27754198	503	514	fundamental	T169	C1527178
27754198	515	519	step	T077	C1261552
27754198	528	534	choice	T055	C0008300
27754198	541	552	appropriate	T080	C1548787
27754198	553	560	therapy	T061	C0087111
27754198	572	579	correct	T080	C2349182
27754198	584	605	arterial hypertension	T047	C0020538
27754198	614	625	hypokalemia	T033	C0020621
27754198	653	659	search	T061	C0557959
27754198	664	666	PA	T047	C1384514
27754198	674	682	majority	T080	C0205164
27754198	690	698	patients	T101	C0030705
27754198	704	716	hypertension	T047	C0020538
27754198	748	752	lack	T080	C0332268
27754198	760	769	classical	T169	C0443177
27754198	770	775	signs	T184	C0037088
27754198	795	819	drug-induced hypokalemia	T034	C0342591
27754198	824	831	related	T080	C0439849
27754198	832	840	symptoms	T184	C1457887
27754198	842	844	PA	T047	C1384514
27754198	854	863	diagnosis	T060	C0430022
27754198	871	879	majority	T080	C0205164
27754198	887	892	cases	T169	C0868928
27754198	898	912	identification	T080	C0205396
27754198	934	955	primary aldosteronism	T047	C1384514
27754198	990	994	some	T081	C0205392
27754198	995	1004	subgroups	T185	C1515021
27754198	1008	1016	patients	T101	C0030705
27754198	1036	1040	drug	T121	C0013227
27754198	1043	1052	resistant	T169	C0332325
27754198	1053	1065	hypertension	T047	C0020538
27754198	1078	1090	high risk of	T033	C0332167
27754198	1091	1112	primary aldosteronism	T047	C1384514
27754198	1128	1147	diagnostic approach	T060	C0430022
27754198	1151	1160	necessary	T169	C1514873
27754198	1170	1178	patients	T101	C0030705
27754198	1188	1195	benefit	T081	C0814225
27754198	1209	1217	accurate	T080	C0443131
27754198	1218	1227	diagnosis	T060	C0430022
27754198	1229	1238	Knowledge	T170	C0376554
27754198	1246	1259	sodium intake	T201	C0489645
27754198	1264	1276	drug effects	T169	C0728866
27754198	1284	1307	aldosterone-renin ratio	T201	C1114689
27754198	1333	1342	diagnosis	T060	C0430022
27754198	1364	1369	cases	T169	C0868928
27754198	1387	1394	work-up	T060	C0750430
27754198	1411	1439	Endocrine Society Guidelines	T170	C0162791
27754198	1444	1453	supported	T077	C1521721
27754198	1461	1468	results	T169	C1274040
27754198	1476	1488	AQUARR Study	T062	C2603343
27754198	1494	1514	diagnostic algorithm	T170	C0679508
27754198	1519	1521	PA	T047	C1384514
27754198	1543	1553	simplified	T052	C2986669
27754198	1589	1601	confirmatory	T080	C0521091
27754198	1602	1607	tests	T060	C0683443
27754198	1616	1621	cases	T169	C0868928
27754198	1631	1640	rendering	T052	C1999230
27754198	1645	1654	screening	T060	C1710031
27754198	1658	1660	PA	T047	C1384514
27754198	1698	1705	centers	T073,T093	C0475309
27754198	1727	1733	use of	T169	C1524063
27754198	1736	1740	cost	T081	C0010186
27754198	1743	1752	effective	T080	C1704419
27754198	1753	1761	strategy	T169	C2700391
27754198	1765	1771	screen	T058	C0220908
27754198	1776	1784	patients	T101	C0030705
27754198	1790	1811	primary aldosteronism	T047	C1384514
27754198	1816	1824	variance	T080	C1711260
27754198	1830	1844	identification	T080	C0205396
27754198	1848	1869	primary aldosteronism	T047	C1384514
27754198	1870	1878	subtypes	T185	C0449560
27754198	1895	1916	adrenal vein sampling	T060	C0457942
27754198	1918	1921	AVS	T060	C0457942
27754198	1953	1978	tertiary referral centers	T073,T093	C0587437
27754198	1989	1999	experience	T041	C0237607
27754198	2003	2013	performing	T055	C0597198
27754198	2018	2030	interpreting	T169	C1285553
27754198	2036	2059	minimally invasive test	T060	C0430022
27754198	2070	2079	long-term	T079	C0443252
27754198	2080	2084	cure	T077	C1880198
27754198	2085	2096	biochemical	T169	C0205474
27754198	2097	2101	cure	T077	C1880198
27754198	2109	2121	consistently	T080	C1524057
27754198	2136	2149	adrenalectomy	T061	C0001632
27754198	2153	2158	based	T169	C1527178
27754198	2162	2165	AVS	T060	C0457942
27754198	2168	2173	based	T169	C1527178
27754198	2174	2188	identification	T080	C0205396
27754198	2204	2215	aldosterone	T109,T121,T125	C0002006
27754198	2216	2222	excess	T080	C1979886
27754198	2234	2243	long-term	T079	C0443252
27754198	2244	2248	cure	T077	C1880198
27754198	2252	2264	hypertension	T047	C0020538
27754198	2277	2279	no	T169	C1518422
27754198	2280	2284	need	T080	C0027552
27754198	2289	2310	antihypertensive drug	T121	C0003364
27754198	2311	2320	treatment	T061	C0013216
27754198	2358	2363	cases	T169	C0868928
27754198	2373	2383	additional	T169	C1524062
27754198	2398	2404	marked	T080	C1706089
27754198	2405	2416	improvement	T077	C2986411
27754198	2420	2442	blood pressure control	T040	C1753303
27754198	2444	2448	Lack	T080	C0332268
27754198	2452	2466	blood pressure	T040	C0005823
27754198	2501	2513	misdiagnosis	T033	C0679838
27754198	2521	2532	concomitant	T079	C0521115
27754198	2533	2555	essential hypertension	T047	C0085580